Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data

Inhibrx Biosciences Inc ( (INBX) ) just unveiled an announcement.

On April 21, 2026, Inhibrx Biosciences reported updated interim results from a Phase 1/2 trial of its DR5 agonist antibody ozekibart (INBRX-109) combined with FOLFIRI in locally advanced or metastatic, unresectable colorectal cancer. As of the April 10, 2026 cutoff, among 45 heavily pretreated, largely fourth-line patients—most of whom had failed prior irinotecan—the regimen delivered a 20% objective response rate versus historical standards of 1–6%.

Median progression-free survival reached 5.5 months, with 42% of patients still progression-free at six months and an overall disease control rate of 87%, while safety remained manageable, dominated by Grade 1–2 gastrointestinal and fatigue-related adverse events and no meaningful liver toxicity despite high rates of liver metastases. The data strengthen the case for ozekibart as a potential new option in late-line colorectal cancer and support Inhibrx’s plans to engage regulators on a first-line registrational program in colorectal cancer, explore accelerated pathways in fourth-line colorectal cancer and refractory Ewing sarcoma, and advance its April 2026 biologics license application for conventional chondrosarcoma, collectively signaling a broadening clinical and regulatory footprint for the asset.

The most recent analyst rating on (INBX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Inhibrx Biosciences Inc stock, see the INBX Stock Forecast page.

Spark’s Take on INBX Stock

According to Spark, TipRanks’ AI Analyst, INBX is a Neutral.

The score is primarily held down by weak financial performance driven by persistent heavy cash burn, recurring losses, and limited revenue scale (despite improved leverage). Technicals are mixed with neutral momentum, while valuation is challenged by negative earnings and no dividend. A positive pipeline/catalyst update provides some support but remains outcome-dependent.

To see Spark’s full report on INBX stock, click here.

More about Inhibrx Biosciences Inc

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel biologic therapeutic candidates using proprietary protein engineering platforms. Spun out of Inhibrx, Inc. in 2024, its current clinical portfolio centers on multivalent antibodies, including ozekibart and INBRX-106, aimed at complex oncology indications with high unmet medical need.

Ozekibart is a precision-engineered, tetravalent DR5 agonist antibody designed to induce tumor-biased cell death. It has previously received Fast Track and orphan drug designations from the U.S. Food and Drug Administration for conventional chondrosarcoma, where it became the first investigational therapy to show a significant progression-free survival benefit in a randomized trial for this rare bone cancer.

In a registrational trial reported in October 2025, ozekibart reduced the risk of disease progression or death by 52% versus placebo in advanced chondrosarcoma, more than doubling median progression-free survival to 5.52 months. These data, along with improvements in disease control and patient-reported outcomes such as pain and physical function, underpin Inhibrx’s strategy to expand ozekibart across multiple solid tumor settings.

Average Trading Volume: 211,006

Technical Sentiment Signal: Buy

Current Market Cap: $1.22B

For detailed information about INBX stock, go to TipRanks’ Stock Analysis page.